HR+/HER2‑ Breast Cancer Market Trends Reflect Rapid Adoption of Personalized Treatments
Breast cancer remains one of the most commonly diagnosed cancers worldwide, with hormone receptor-positive and HER2-negative subtypes accounting for a significant proportion of total cases. Advancements in targeted therapies, personalized treatment approaches, and increasing awareness regarding early diagnosis are transforming …